Life Science Compliance Update

May

2017

The Financial Risk of Waiting – 340B, Duplicate Discounts and Diversion

Written by , Posted in Pricing

Clay Willis, Life Science Director and Chris Cobourn, Managing Director, Huron Life Sciences

The purpose of this article is give manufacturers some initial background on the topics and some tools that could be considered. The review methodology described has been proven to help manufacturers and has been the starting point for developing an on-going monitoring.

Menu Title